Background/Objective: Previous studies conducted both in the general and diabetic population have shown that pulse pressure (PP) can predict mortality from cardiovascular diseases. The aim of the present study was to investigate the relationship between PP and specific cardiovascular mortality, i.e. from cerebrovascular and ischemic heart diseases, in a well-characterized cohort of type 2 diabetic patients. Methods: A cohort of 1,128 known type 2 diabetic patients 56 to 74 years of age with at least 2 blood pressure measurements for each year between 1984–1986 was followed-up for ten years to assess specific causes of death. The analyses were carried out by using the mean and the coefficient of variation (CV) of PP. Results: By the end of the 10-year follow-up period, 375 patients (178 male, 197 female) had died (33%). The mean PP resulted as an independent predictor of all causes and cardiovascular mortality. Remarkably, the mean PP, but not the CV of PP, was highly predictive of mortality from cerebrovascular diseases. The risk of cerebrovascular mortality rose by 86% with a 10 mm Hg increase in mean PP. PP turned out to be the most important predictor of cerebrovascular mortality among various pressure indexes (mean, systolic and diastolic pressure). Conclusion: The mean pulse pressure, but not the coefficient of variation is a strong predictor of cardiovascular mortality, mainly from cerebrovascular diseases, in type 2 diabetic patients.

Keywords:
Pulse pressure, Type 2 diabetes, Cardiovascular diseases, Mortality
1.
Kannel WB, Wilson PW, Zhang TJ: The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 1991;121:1268–1273.
2.
Franklin SS: Do diabetes and hypertension interact to accelerate vascular ageing? J Hypertens 2002;20:1693–1696.
3.
Safar ME: Pulse pressure in essential hypertension: clinical and therapeutical implications. J Hypertens 1989;7:769–776.
4.
Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull W Jr, Richardson M, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, et al: A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committe on vascular lesions of the Council on Arteriosclerosis. American Heart Association. Arterioscler Thromb 1992;12:120–134.
5.
Boutouyrie P, Bussy C, Lacolley P, Girerd X, Laloux B, Laurent S: Association between local pulse pressure, mean blood pressure, and large-artery remodeling. Circulation 1999;100:1387–1393.
6.
Girerd X, Mourad JJ, Copie X, Moulin C, Acar C, Safar M, Laurent S: Noninvasive detection of an increased vascular mass in untreated hypertensive patients. Am J Hypertens 1994;7:1076–1084.
7.
Wilkinson IB, Franklin SS, Hall IR, Tyrrell S, Cockcroft JR: Pressure amplification explains why pulse pressure is unrelated to risk in young subjects. Hypertension 2001;38:1461–1466.
8.
Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D: Hemodynamic patterns of age-related changes in blood pressure: the Framingham Heart Study. Circulation 1997;96:308–315.
9.
Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JL, Ducimetiere P, Guize L: Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997;30:1410–1415.
10.
Benetos A, Rudnichi A, Safar M, Guize L: Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension 1998;32:560–564.
11.
Salomaa V, Riley W, Kark JD, Nardo C, Folsom AR: Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC study. Atherosclerosis Risk in Community Study. Circulation 1995;91:1432–1433.
12.
Schram MT, Kostense PJ, van Dijk RA, Dekker JM, Nijpels G, Bouter LM, Heine RJ, Stehouwer CA: Diabetes, pulse pressure and cardiovascular mortality: the Hoorn Study. J Hypertens 2002;20:1743–1751.
13.
Muggeo M, Verlato G, Bonora E, Bressan F, Girotto S, Corbellini M, Gemma ML, Moghetti P, Zenere M, Cacciatori V, Zoppini G, deMarco R: The Verona Diabetes Study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality. Diabetologia 1995;38:318–325.
14.
Cox DR: Regression models and life-tables (with discussion). J Royal Stat Soc, B 1972;34:187–220.
15.
Franklin SS, Khan SA, Wong ND, Larson MG, Levy D: Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 1999;100:354–360.
16.
Millar JA, Lever AF, Burke V: Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. J Hypertens 1999;17:1065–1072.
17.
Borghi C, Dormi A, Ambrosioni E, Gaddi A; on behalf of the Brisighella Heart Study working party: Relative role of systolic, diastolic and pulse pressure as risk factors for cardiovascular events in the Brisighella Heart study. J Hypertens 2002;20:1737–1742.
18.
Mitchell GF, Moye LA, Braunwald E, Rouleau JL, Bernstein V, Geltman EM, Flaker GC, Pfeffer MA: Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival Ventricular Enlargement. Circulation 1997;96:4254–4260.
19.
Miura K, Dyer AR, Greenland P, Daviglus ML, Hill MA, Liu K, Garside DB, Stamler J; Chicago Heart Study: Pulse pressure compared with other blood pressure indexes in the prediction of 25-year cardiovascular and all-cause mortality rates. The Chicago Heart Association Detection Project in Industry Study. Hypertension 2001;38:232–237.
20.
Darne B, Girerd X, Safar M, Cambien F, Guize L: Pulsatile versus steady component of blood pressure: a cross-sectional analysis and a prospective analysis on cardiovascular mortality. Hypertension 1989;13:392–400.
21.
Hoffman JI: A critical view of coronary reserve. Circulation 1987;75(suppl 1):I6–I11.
22.
Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension and cardiovascular disease: an update. Hypertension 2001;37:1053–1059.
23.
Singh R, Barden A, Mori T, Beilin L: Advanced glycation end-products: a review. Diabetologia 2001;44:129–146.
24.
Giannattasio C, Failla M, Grappiolo A, Gamba PL, Paleari F, Mancia G: Progression of large artery structural and functional alterations in type 1 diabetes. Diabetologia 2001;44:203–208.
25.
Lambert J, Smulders RA, Aarsen M, Donker AJ, Stehouwer CD: Carotid artery stiffness is increased in microalbuminuric IDDM patients. Diabetes Care 1998;21:99–103.
26.
Aviv A: Hypothesis: pulse pressure and human longevity. Hypertension 2001;37:1060–1066.
27.
Dart AM, Kingwell BA: Pulse pressure – a review of mechanisms and clinical relevance. J Am Coll Cardiol 2001;37:975–984.
28.
Antikainen RL, Jousilahti P, Vanhanen H, Tuomilehto J: Excess mortality associated with increased pulse pressure among middle-aged men and women is explained by high systolic blood pressure. J Hypertens 2000;18:417–423.
29.
Vemmos KN, Tsivgoulis G, Spengos K, Manios E, Daffertshofer M, Kotsis V, Lekakis JP, Zakopoulos N: Pulse pressure in acute stroke is an independent predictor of long-term mortality. Cerebrovasc Dis 2004;19:30–36.
30.
Safar ME: Pulse pressure, heart rate, and drug treatment of hypertension. Curr Hypertens Rep 2004;6:190–194.
© 2007 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.